Connor Clark & Lunn Investment Management Ltd. Cuts Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Connor Clark & Lunn Investment Management Ltd. decreased its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 19.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,367 shares of the company's stock after selling 16,306 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.14% of Amphastar Pharmaceuticals worth $2,501,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of AMPH. Smartleaf Asset Management LLC grew its stake in shares of Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock worth $26,000 after purchasing an additional 493 shares during the period. Parkside Financial Bank & Trust grew its stake in shares of Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock worth $36,000 after purchasing an additional 871 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock worth $56,000 after purchasing an additional 398 shares during the period. KBC Group NV grew its stake in shares of Amphastar Pharmaceuticals by 43.1% during the 4th quarter. KBC Group NV now owns 2,159 shares of the company's stock worth $80,000 after purchasing an additional 650 shares during the period. Finally, PNC Financial Services Group Inc. grew its stake in shares of Amphastar Pharmaceuticals by 90.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company's stock worth $156,000 after purchasing an additional 1,992 shares during the period. Hedge funds and other institutional investors own 65.09% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares of the company's stock, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 27.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AMPH. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 price objective on the stock. Piper Sandler lowered their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday.

Amphastar Pharmaceuticals Price Performance

NASDAQ AMPH traded up $0.38 during trading hours on Friday, reaching $28.29. The company's stock had a trading volume of 1,478,691 shares, compared to its average volume of 426,268. The stock has a market cap of $1.35 billion, a PE ratio of 9.43, a PEG ratio of 2.19 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $25.89 and a fifty-two week high of $53.96. The company's 50-day moving average is $31.91 and its two-hundred day moving average is $40.57. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.